Tejas Gunjikar
Application Development and Innovation Leader
Ask Joshua Katz what he does in his spare time, and he’ll tell you he has very little of it! Between raising four kids, being involved with his synagogue, and his ground-breaking biopharma work at IFF Pharma Solutions, he fills every minute of the day and wouldn’t have it any other way.
An award-winning scientist with a passion for human health, Josh is a technical service expert for Pharma Solutions’ revolutionary NovaMatrix® portfolio which produces and supplies ultrapure biopolymers for biomedical applications.
“My background is in chemistry, but I see myself at the intersection of many disciplines,” said Josh. “Chemistry, polymer science, biology and medicine are all areas that our work at Pharma Solutions draws from. Bringing these unique areas together differentiates us and drives innovative solutions for our customers.”
He began working in formulation science with Dow and quickly moved into the pharma business after the Dow/DuPont merger. Through the subsequent merger with IFF, Josh now leads a global team of experts working on key biopharma projects. With advanced degrees from MIT and University of Pennsylvania, as well as numerous awards, patents, and scientific publications, Josh could’ve had an illustrious career in academia. However, sage advice from his wife made him realize that the healthcare industry is where he wanted to focus. “We’re all gifted with an ability to make the world a better place. I’m fortunate enough to be able to channel that towards human health,” said Josh.
When he does get some down time, you can be sure he’s doing something sports-related! Whether coaching his son’s soccer team or lacing up his own ice skates to play hockey, Josh is always on the go. We’re so grateful that Josh brings that same energy, passion and focus to his work every day.
Tejas Gunjikar
Application Development and Innovation Leader
Elizabeth Tocce
Lead Applications Scientist
Nasrin Mahmoudi
Senior Lead Applications Scientist
Roland Adden
Vice President R&D